Key result
Doublet chemotherapy with ifosfamide and epirubicin led to marked regression of the intraluminal hypoattenuated area in a 63-year-old woman with pulmonary artery sarcoma.
Why the study?
Does a two-drug combination chemotherapy consisting of ifosfamide and epirubicin improve pulmonary artery sarcoma in a patient with residual disease post-thromboectomy?
Case Report (n=1)
No
Does a two-drug combination chemotherapy consisting of ifosfamide and epirubicin improve pulmonary artery sarcoma in a patient with residual disease post-thromboectomy?
This case report suggests that intensive chemotherapy with ifosfamide and epirubicin may be an effective treatment option for unresectable pulmonary artery sarcoma.
No takes yet. Share an insight, caveat, or question.
Chemotherapy after resection may benefit pulmonary artery intimal sarcoma; leaves open optimal regimens and survival benefit in larger cohorts.
Uchida et al. (2005) conducted a case report in Pulmonary artery sarcoma (n=1). Ifosfamide and epirubicin was evaluated on Regression of the intraluminal hypoattenuated area on CT scan. Doublet chemotherapy with ifosfamide and epirubicin led to marked regression of the intraluminal hypoattenuated area in a 63-year-old woman with pulmonary artery sarcoma.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: